Physician profile
Mei Chen
NPI 1548588189
$4,219.85
in general payments reported to CMS, 2019-2025
27 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 89% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $400 · 2023: $1,083 · 2024: $1,004 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,248.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $465.14 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $372.82 | 2021-2025 | Verquvo, Capvaxive, Keytruda |
| Boston Scientific Corporation | $333.68 | 2021-2023 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $327.05 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $293.62 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $273.04 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $265.85 | 2021-2025 | |
| Bridgebio Pharma, INC. | $205.92 | 2025 | Attruby |
| Abiomed | $183.94 | 2024-2025 | Impella |
| Sequel Med Tech, LLC | $171.78 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $167.85 | 2021-2025 | Farxiga, Lokelma, Wainua |
| Impulse Dynamics (USA) INC. | $162.89 | 2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $161.31 | 2021-2024 | Uptravi, Opsumit |
| Azurity Pharmaceuticals, INC. | $156.25 | 2023-2025 | Edarbi, Edarbi, Horizant |
| Amgen INC. | $139.66 | 2023-2025 | Repatha, Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $120.65 | 2023-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.15 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.75 | 2022-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $51.17 | 2022-2023 | |
| Vifor Pharma, INC. | $46.85 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $38.01 | 2024 | Dupixent |
| Chiesi USA, INC. | $33.30 | 2025 | Kengreal |
| Lilly USA, LLC | $26.61 | 2021 | |
| Amarin Pharma, INC. | $17.40 | 2021 | |
| Tactile Systems Technology INC | $15.74 | 2024 | Entre Plus, Flexitouch Plus |
| Abbott Laboratories | $14.43 | 2021 | |
| Scpharmaceuticals INC. | $12.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mei Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.